Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial.

We conducted a double-blind, placebo-controlled, randomized crossover study to evaluate the safety and immunogenicity of a single 5 x 10(8)-CFU dose of live oral recombinant cholera vaccine CVD 103-HgR in 94 North American adults. The vaccine was well tolerated without associated adverse reactions....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Infect Immun
Hauptverfasser: Kotloff, K L, Wasserman, S S, O'Donnell, S, Losonsky, G A, Cryz, S J, Levine, M M
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology (ASM) 1992
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC257485/
https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1398956/
https://ncbi.nlm.nih.govhttps://doi.org/10.1128/iai.60.10.4430-4432.1992
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge